Table 4.
Analysis of OS prognostic factors in unresectable HCC patients.
| Variable | N | mOS(month) | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|---|
| P value | HR | 95% CI | P value | HR | 95% CI | |||
| Age(<60/≥60) | 93/78 | 14.9/15.5 | 0.831 | 1.043 | 0.711~1.529 | |||
| Gender(Male/Female) | 144/27 | 15.5/14 | 0.394 | 1.249 | 0.749~2.084 | |||
| ECOG-PS(≤1/2) | 113/58 | 18/8.9 | 0.005 | 1.752 | 1.184~2.594 | 0.001 | 2.064 | 1.335~3.191 |
| Child-Pugh class(A/B) | 120/51 | 18.3/8.3 | 0.001 | 1.924 | 1.296~2.856 | |||
| BCLC(A+B/C) | 112/59 | 17.8/10.9 | 0.033 | 1.527 | 1.034~2.257 | |||
| Portal vein tumor thrombus(Yes/No) | 57/114 | 10.9/17.8 | 0.042 | 1.501 | 1.014~2.222 | |||
| Tumor number(Single/Multiple) | 63/108 | 17.6/15.5 | 0.942 | 1.016 | 0.671~1.538 | |||
| Tumor size(<10/≥10) | 93/78 | 17.6/12.1 | 0.027 | 1.546 | 1.052~2.271 | |||
| Hepatitis B virus(+/-) | 147/24 | 14.6/22.9 | 0.03 | 2.062 | 1.074~3.958 | 0.007 | 2.539 | 1.291~4.993 |
| AFP(<400/≥400) | 83/88 | 12.0/18.0 | 0.03 | 1.535 | 1.042~2.259 | 0.013 | 1.72 | 1.12~2.643 |
| ALT(<40/≥40) | 81/90 | 17.6/14.6 | 0.337 | 0.91 | 0.751~1.103 | |||
| NLR(<2.195/≥2.195) | 73/98 | 20.4/11.6 | 0.001 | 2.024 | 1.345~3.044 | 0.023 | 1.669 | 1.073~2.597 |
| Treatment options(TACE/TACE+TKI/TACE+TKI+ICIs) | 45/76/50 | 11.4/14.9/24.1 | 0.001 | 0.615 | 0.466~0.81 | <0.001 | 0.544 | 0.402~0.736 |
TACE, transcatheter arterial chemoembolization; TKI, tyrosine kinase inhibitors; ICIs, immune checkpoint inhibitors; ECOG-PS, Eastern Cooperative Oncology Group performance status; BCLC, Barcelona Clinic Liver Cancer; AFP, alpha-fetoprotein; ALT, alamine aminotransferase; NLR, neutrophil-lymphocyte ratio; mOS, overall survival.